779353-65-0

Usage

Uses

Used in Pharmaceutical Industry:
3-((5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide is used as a potential drug candidate for the development of new medications due to its unique structure and possible biological activity. Its specific application reason is not provided in the materials, but its potential use in the pharmaceutical industry is based on the assumption that its structure may confer beneficial properties for treating certain medical conditions.
Since the provided materials do not specify particular applications or industries for 3-((5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide, the above use is a general statement based on the compound's potential pharmaceutical relevance. Further research and development would be required to determine its exact applications and efficacy in specific medical conditions.

Upstream product

• 779353-64-9 5,7-dichloro-3-ethylpyrazolo[1,5-a]pyrimidine 
• 106940-10-7 3-(aminomethyl)pyridine N-oxide hydrochloride 

Downstream Products

• 779353-01-4 Dinaciclib 
• 779353-04-7 C₂₁H₂₈N₆O₂ 

Relevant academic research and scientific papers

Discovery of dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases

Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability paramete

Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates

This application discloses a novel process to synthesize (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives, and intermediates useful in the synthesis thereof. The subject (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives are useful as cyclin-dependent kinase inhibitor compounds (CDK inhibitors) in pharmaceutical preparations.